GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises

GenSight Biologics Provides Financial and Operational Update

Annual General Meeting on June 21, 2023

GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023

GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update

GenSight Biologics Withdraws its EMA Application for LUMEVOQ®

GenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations Findings

GenSight Biologics Reports Full Year 2022 Consolidated Financial Results

GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial